Finance, Grants, Deals

Nightstar recruits executive after Series C

UK-based Nightstar Ltd has recruited David Lubner to its board of directors less than a month after raising $45 million in a Series C financing round to advance its lead gene therapy product for choroideremia, an inherited cause of progressive blindness.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Ablynx secures deal with Sanofi

Ablynx NV has secured a collaboration with Sanofi SA to develop products directed at immune-mediated inflammatory diseases. The deal, which includes an upfront payment of €23 million, is the latest endorsement of the Belgian company’s therapeutic protein platform.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium

Sanofi to acquire Protein Sciences

Sanofi has taken steps to broaden its vaccine portfolio with the planned acquisition of Protein Sciences Corp of Meriden, Connecticut, US which has a protein-based influenza vaccine recently approved for the US market.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France

Analysis: Syncona unveils strategy after merger

Syncona Investment Management Ltd, an investment company in which the Wellcome Trust has a significant holding, reported total net assets of £895 million at the end of its fiscal year on 31 March, up from £472 million a year earlier. This follows its merger in November 2016 with BACIT Ltd, an investor in diversified portfolios based in the Guernsey Islands.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

AI company to collaborate with GSK

A UK-based company that uses artificial intelligence for drug discovery has entered into a collaboration with GlaxoSmithKline Plc to discover candidate small molecules against up to 10 disease-related targets. Exscientia Ltd is a 2012 spin-out of the University of Dundee.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Evotec expands capacity in iPS cell generation

Evotec AG has expanded its capacity to discover new drugs through the use of adult stem cells that have been reprogrammed to produce any type of cell in the human body. These induced pluripotent stem (iPS) cells can be used to model disease and identify prospective treatments.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany

BioGeneration Ventures tops up third fund

Netherlands-based BioGeneration Ventures has secured new commitments for its third investment fund, BGV III, enabling it to expand the number of companies to which it provides seed capital. The new commitments raise the fund’s capital to €66 million.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Netherlands

Chinese acquire German biologics firm

China’s Creat Group Corp, one of the country’s large investors in foreign companies, is purchasing Germany’s Biotest AG, a Frankfurt Stock Exchange-listed biologics company, for about €1.2 billion.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany

UK medical charity benefits from Keytruda

A UK medical charity has decided that royalty income from intellectual property that it licensed to the developers of Keytruda, should be reinvested in innovation. The charity, LifeArc, has therefore set up two new funds to support academic research and early-stage biotech companies.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Medicxi launches $300 million fund for late-stage assets

It has been a little more than a year since Medicxi Ventures (UK) LLP was spun out of Index Ventures to provide capital to early life science in Europe. Now, the venture fund has expanded its reach with the launch of a new fund that will finance later stage assets.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Syndicate content